1.17 USD
-0.03 (-2.5%)
At close: Jul 17, 2025
0.67 USD
-0.5 (-42.74%)
After Hours: 7/17/2025, 8:04:41 PM
Overall BCLI gets a fundamental rating of 1 out of 10. We evaluated BCLI against 524 industry peers in the Biotechnology industry. BCLI has a bad profitability rating. Also its financial health evaluation is rather negative. BCLI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year BCLI has reported negative net income.
- In the past year BCLI has reported a negative cash flow from operations.
- BCLI had negative earnings in each of the past 5 years.
- BCLI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of BCLI (-310.45%) is worse than 92.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -310.45% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-443.44%
ROA(5y)-295.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BCLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for BCLI has been increased compared to 1 year ago.
- BCLI has less shares outstanding than it did 5 years ago.
- BCLI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -103.72, we must say that BCLI is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -103.72, BCLI is not doing good in the industry: 96.04% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -103.72 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- BCLI has a Current Ratio of 0.21. This is a bad value and indicates that BCLI is not financially healthy enough and could expect problems in meeting its short term obligations.
- BCLI has a Current ratio of 0.21. This is amonst the worse of the industry: BCLI underperforms 94.96% of its industry peers.
- A Quick Ratio of 0.21 indicates that BCLI may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.21, BCLI is doing worse than 94.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.21 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
- BCLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, BCLI will show a very strong growth in Earnings Per Share. The EPS will grow by 22.11% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.08%
EPS Next 2Y25.71%
EPS Next 3Y18.1%
EPS Next 5Y22.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- BCLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year BCLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as BCLI's earnings are expected to grow with 18.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.71%
EPS Next 3Y18.1%
5. Dividend
5.1 Amount
- No dividends for BCLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BRAINSTORM CELL THERAPEUTICS / BCLI FAQ
What is the ChartMill fundamental rating of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
ChartMill assigns a fundamental rating of 1 / 10 to BCLI.
Can you provide the valuation status for BRAINSTORM CELL THERAPEUTICS?
ChartMill assigns a valuation rating of 0 / 10 to BRAINSTORM CELL THERAPEUTICS (BCLI). This can be considered as Overvalued.
What is the profitability of BCLI stock?
BRAINSTORM CELL THERAPEUTICS (BCLI) has a profitability rating of 0 / 10.
Can you provide the financial health for BCLI stock?
The financial health rating of BRAINSTORM CELL THERAPEUTICS (BCLI) is 1 / 10.
What is the expected EPS growth for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
The Earnings per Share (EPS) of BRAINSTORM CELL THERAPEUTICS (BCLI) is expected to grow by 33.08% in the next year.